![]() Body weight (in AS) and disease activity status at baseline (particularly in PsA) significantly affected disease activity changes. Significant reductions in ASDAS-CRP and DAS28-CRP were observed at all time-points. Overall, mean disease duration was 6.7 years and biologic-naïve patients were 85%. ResultsĮighty-five adult patients with active disease (29 with AS and 56 with PsA 23 males and 62 females) were treated. Data were collected at baseline and after 8, 24, and 52 weeks of treatment. ASDAS-CRP and DAS28-CRP scores were used to measure axial and peripheral disease activity in AS and PsA, respectively. We retrospectively analyzed medical records of outpatients with AS or PsA treated with secukinumab between December 2017 and December 2019. Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients. Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |